Akorn Inc (AKRX.O)
20 Dec 2013
|Market Cap (Mil.):||$2,399.29|
|Shares Outstanding (Mil.):||96.36|
- Generic drugmaker Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million to expand its eye drug portfolio to oral liquids and ointments.
Aug 27 - Specialty pharmaceutical company Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million in cash to expand its eye drug portfolio to other dosage forms such as oral liquids, topical creams and ointments.
|Sun Pharmaceutical Industries Limited (SUN.NS)||Rs578.90||-4.00|
|Sun Pharmaceutical Industries Limited (SUN_p.NS)||--||--|
|Novartis AG (NOVN.VX)||CHF70.45||+0.05|
|Teva Pharmaceutical Industries Limited (TEVA.TA)||13,920.00₪||-30.00|
|Pfizer Limited (PFIZ.NS)||Rs1,177.30||-0.10|
|Allergan, Inc. (AGN.N)||$107.73||+3.97|
|Hospira, Inc. (HSP.N)||$41.27||+0.22|
|Fresenius Kabi Pharma. Holding Inc (APCVZ.OQ)||--||--|
|Hikma Pharmaceuticals Plc (HIK.L)||1,210.00p||-8.00|
|Sagent Pharmaceuticals Inc (SGNT.OQ)||$24.80||+0.09|
Earnings vs. Estimates
Analyst Research Reports
Provider: Thomson Reuters Stock Report
Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of AKORN INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation.
Provider: Jefferson Research
Provider: ValuEngine, Inc.
Provider: Wright Reports
Provider: Pechala's Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.